Pylopass®
Product description
» Proprietary strain: Pylopass® is a Lactobacillus reuteri DSMZ 17648, which
specifically binds and coaggregates with H. pylori to reduce the bacterial load.
» Efficiency: Pylopass® decrease the risk of developing gastritis and peptic ulcer disease and can increase the efficacy of Antibiotics treatment. » No side effects: Pylopass® does not alter the microflora of the gut and does not contribute to the antibiotic resistance.
Reduction of H. pylori load in 60% of the subjects in only 2 weeks
Patented Mechanism of Action: Pylopass® is able to recognize surface structures on H. pylori and to form coaggregates. Those Co-aggregates are eliminated from the organism through the gastrointestinal tract. This leads to a reduction of Helicobacter pylori load in the stomach.
Read more
» Efficiency: Pylopass® decrease the risk of developing gastritis and peptic ulcer disease and can increase the efficacy of Antibiotics treatment. » No side effects: Pylopass® does not alter the microflora of the gut and does not contribute to the antibiotic resistance.
Reduction of H. pylori load in 60% of the subjects in only 2 weeks
Patented Mechanism of Action: Pylopass® is able to recognize surface structures on H. pylori and to form coaggregates. Those Co-aggregates are eliminated from the organism through the gastrointestinal tract. This leads to a reduction of Helicobacter pylori load in the stomach.
Specifications
| Categories | Food Supplements / Nutraceuticals |
|---|---|
| Supplied from | Spain |
| Product Certifications | Sustainable Seafood |
Pylopass®
